News
Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.
Show by Tag
NovaVive and Hoken Biotechnology have committed to work together to introduce Amplimune™ to Asian markets. Hoken will conduct clinical studies to support regulatory submissions and will be our sales and marketing agent.
An equine-specific version of Immunocidin® for equine sarcoid tumors is now available to Canadian veterinarians. The new product, Immunocidin® Equine, is packaged in 5mL vials and is approved by the Canadian regulator (CFIA).
NovaVive today presented a Research Report at the 2017 ACVIM Forum in National Harbor, Maryland. The report summarized the results of a study conducted in a large Canadian veal operation with Amplimune™.
NovaVive now offers an equine-specific version of its Immunocidin® product for equine sarcoids in response to demand by U.S. veterinarians. Immunocidin® Equine is packaged in 5mL vials for the convenience of practitioners.
Amplimune™ is now available to Canadian veterinarians. Amplimune is an immunomodulator that reduces the clinical signs/mortality associated with E. coli diarrhea in neonatal calves. It offers an alternative to antibiotics.
Amplimune™ has received approval for sale in Canada by the Canadian Food Inspection Agency. The Company believes this is the first antibiotic alternative therapy for livestock to receive Canadian regulatory approval.